Braidwell LP Immatics N.V. Transaction History

Braidwell LP

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	BUY	$6.73 - $11.21 $12.5 Million - $20.8 Million	1,856,400 Added 112.68%	3,503,965 $24.9 Million
Q3 2024 Nov 14, 2024	BUY	$10.93 - $12.92 $18 Million - $21.3 Million	1,647,565 New	1,647,565 $18.8 Billion
Q1 2023 May 15, 2023	SELL	$6.74 - $9.44 $6.25 Million - $8.76 Million	-927,765 Reduced 74.22%	322,287 $2.22 Billion
Q4 2022 Feb 14, 2023	BUY	$8.05 - $11.58 $10.1 Million - $14.5 Million	1,250,052 New	1,250,052 $10.9 Billion

91.5M

201K

109K

Ticker IMTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,227,000
Market Cap $390M
Description
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive c...

Get notified when there are updates to the investment portfolio of Braidwell LP, based on Form 13F filings with the SEC.

Stay updated on Braidwell LP with notifications on news.